Avid Bioservices: Quasar Medical Transforms into Comprehensive CDMO with Nordson Acquisition
- Avid Bioservices enhances its position as a key player in the medical device industry through strategic acquisitions.
- The acquisition allows Avid Bioservices to provide integrated development and manufacturing solutions for medical device innovators.
- Avid Bioservices aims to drive innovation and improve time to market for clients in a competitive landscape.
Quasar Medical Transforms into a Comprehensive CDMO with Strategic Acquisition
Quasar Medical recently announces a transformative acquisition of Nordson Corporation's design and development contract manufacturing businesses located in Galway, Ireland, and Tecate, Mexico. This significant move elevates Quasar into a fully integrated Contract Development and Manufacturing Organization (CDMO), allowing the company to provide extensive concept-to-commercialization solutions tailored for medical device original equipment manufacturers (OEMs) and innovators. By bolstering its capabilities, Quasar positions itself as a pivotal player in the evolving medical device landscape, marking a decisive step toward enhancing its service offerings and broadening its market reach.
The acquisition results in an expansion of Quasar’s workforce by nearly 200 employees, including skilled development engineers and technicians, thereby creating new career opportunities in the growing sector. CEO Alex Wallstein highlights how this acquisition not only strengthens Quasar's partnerships with customers and suppliers but also enhances its global presence. By integrating Nordson's operations, Quasar aims to drive innovation and expedite time to market for its clients, which is crucial in the competitive medical device industry. The newly acquired facilities are both FDA-registered and ISO 13485-certified, which underscores Quasar’s commitment to maintaining high standards in quality and compliance.
The strategic positioning of the Galway and Tecate sites in key MedTech regions further optimizes customer proximity and access, enhancing operational efficiency. The Galway facility is poised to emerge as an innovation hub, specializing in advanced product design, prototyping, and clinical innovation. Meanwhile, the Tecate site will focus on cost-effective, high-volume manufacturing, ensuring smoother transitions from development to commercialization. COO Aviel Bohnik emphasizes this acquisition not merely as a growth strategy but as a means to redefine Quasar's role in the industry, transitioning from a manufacturer to a strategic partner that offers a differentiated platform combining innovation, scalability, and operational excellence.
In addition to the operational enhancements, this acquisition positions Quasar Medical to address the increasing demand for sophisticated interventional devices. The integration of Nordson Medical's capabilities allows Quasar to deliver seamless, end-to-end solutions, reinforcing its commitment to delivering high-value offerings across global markets. As the medical device sector continues to evolve, Quasar's strategic pivot enhances its competitive edge, showcasing its dedication to innovation and customer-focused solutions.
Furthermore, this acquisition aligns with industry trends favoring partnerships that provide holistic services in the medical device market. As companies increasingly seek integrated solutions to streamline their product development and manufacturing processes, Quasar's evolution into a comprehensive CDMO is timely, positioning it well for future growth in a rapidly changing landscape.
